Tiltan Pharma is a biopharmaceutical company that developed a proprietary anti-angiogenic and immune modulatory platform for the treatment of cancer. The company'sleading product, TL-118, is an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties. TL-118 repurposes four approved drugs with known safety profiles, combined as an anticancer therapy in a low-dose, high-frequency regimen. TL-118 has beentested in numerous animal tumor models and over 150 cancer patients.
Tiltan is conducting a randomized, open-label phase-IIb clinical trial in metastatic pancreatic cancer under an FDA-approved investigational new drug application. The trial is being conducted in Israel and Eastern Europe as well as in US investigator-initiated studies.